LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 1047Z 
Lipoxen PLC 
15 September 2009 
 

Lipoxen PLC 
("Lipoxen" or "the Company") 
 
 
Additional listing 
 
 
London, UK, 15 September 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical 
company specialising in the development of high value differentiated 
biologicals, vaccines and siRNA delivery, announces that application has been 
made to AIM, a market of the London Stock Exchange plc, for the admission of 
52,000 ordinary shares of 0.5p each (the "New Ordinary Shares"). 
 
 
The New Ordinary Shares are being admitted pursuant to the exercise of options 
under the Lipoxen Plc Unapproved Share Option Plan. 
 
 
It is expected that dealing in the New Ordinary Shares, which will rank pari 
passu in all respects with the existing issued share capital of the Company, 
will commence on 16 September 2009. 
 
 
Enquiries 
 
 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    +44 (0)20 7691 3583  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     +44 (0)20 3205 7500 | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating / Claes Spång                      |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |   +44 (0) 20 7763 2200  | 
+-------------------------------------------------+-------------------------+ 
| John Llewellyn-Lloyd / Sam Reynolds             |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     +44 (0)20 7466 5000 | 
+-------------------------------------------------+-------------------------+ 
| Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye  |                         | 
| Dietrich, Catherine Breen                       |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 LISEALNSFADNEFE 
 

Lipoxen (LSE:LPX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jan 2024 to Jan 2025